Capricor Therapeutics CAPR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$33.94M-12.5% | -$30.17M-22.8% | -$24.57M+5.2% | -$25.91M-6.2% | -$24.39M-243% | ||
| $534.67K+6.4% | $502.59K+1.6% | $494.73K+1.7% | $486.28K+19.9% | $405.45K+7.9% | ||
| $5.92M+54.1% | $3.84M-3.9% | $4M+9.6% | $3.65M-33.5% | $5.48M+139% | ||
| -$3.08M-242% | $2.17M+123% | $971.65K-36.4% | $1.53M+16.2% | $1.32M-20.8% | ||
| -$979.78K-129% | $3.33M+244% | $966.33K+777% | -$142.77K-157% | -$55.47K-105% | ||
| $6.59K— | —— | —— | —— | -$150.67K— | ||
| -$29.25M-24.1% | -$23.57M-19.7% | -$19.69M+2.2% | -$20.12M-213% | -$6.43M+56.5% | ||
| $5.12M+208% | $1.66M+2,881% | $55.84K-80.6% | $287.74K-67.9% | $896.01K+83.3% | ||
| -$154.64M-459% | $43.09M+170% | $15.95M+9.6% | $14.55M-39.1% | $23.89M+119% | ||
| $1.47M-99.4% | $236.96M+3,409,354% | $6.95K-64.5% | $19.58K-61.1% | $50.35K-99.9% | ||
| $1.47M-99.4% | $248.82M+3,579,978% | $6.95K-64.5% | $19.58K-61.1% | $50.35K-99.9% | ||
| -$182.43M-168% | $268.34M— | —— | —— | $17.51M+131% | ||
| -$358.63K— | —— | —— | —— | —— | ||
| -$59.17K— | $0+100% | -$342-5.2% | -$325+100.0% | -$10.31M— | ||
| -$3.08M-242% | $2.17M+123% | $971.65K-36.4% | $1.53M+16.2% | $1.32M-20.8% | ||
| -$979.78K-129% | $3.33M+244% | $966.33K+777% | -$142.77K-157% | -$55.47K-105% | ||
| $641.29K+72.5% | $371.87K-1.4% | $377.28K+2,340% | -$16.84K0.0% | -$16.84K-3.2% | ||
| $6.59K— | —— | —— | —— | -$150.67K— | ||
| —— | —— | —— | —— | $257.46K— | ||
| $5.92M+54.1% | $3.84M-3.9% | $4M+9.6% | $3.65M-33.5% | $5.48M+139% | ||
| $4.7M+35.9% | $3.46M-12.3% | $3.95M— | —— | —— | ||
| $921.75K— | $0-100% | $8.53K-93.5% | $130.73K-46.5% | $244.28K-0.7% | ||
| —— | $761.43K0.0% | $761.43K0.0% | $761.43K0.0% | $761.43K— | ||
| -$34.38M-36.2% | -$25.23M-27.8% | -$19.74M+3.3% | -$20.41M-178% | -$7.33M+52.0% | ||
| -$34.38M-36.2% | -$25.23M-27.8% | -$19.74M+3.3% | -$20.41M-178% | -$7.33M+52.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Capricor Therapeutics generate?
- Capricor Therapeutics (CAPR) generated -$92.6M in operating cash flow over the trailing twelve months.
- What is Capricor Therapeutics's free cash flow?
- After $7.1M of capital expenditures, Capricor Therapeutics's free cash flow was -$99.8M over the trailing twelve months, down 114.0% year over year.
- Where does Capricor Therapeutics's cash flow data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.